Pursuant to Section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a registration under Section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with § 1301.34 of Title 21 Code of Federal Regulations (CFR), notice is hereby given that on January 8, 2003, Sigma Aldrich Company, Subsidiary of Sigma-Aldrich Corporation, 3500 Dekalb Street, St. Louis, Missouri 63118, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:
|Gamma Hydroxybutyric Acid (2010)||I|
|Lysergic acid diethylamide (7315)||I|
|4-Bromo-2, 5-dimethoxyamphetamine (7391)||I|
|4-Bromo-2, 5-dimethoxyamphetamine (7392)||I|
|2, 5-Dimethoxyamphetamine (7396)||I|
|3, 4-Methylenedioxyamphetamine (7400)||I|
|N-Hydroxy-3, 4-methylenedioxyamphetamine (7402)||I|
|3, 4-Methylenedioxy-N-ethylamphetamine (7404)||I|
|3, 4-Methylenedioxymethamphetamine (7405)||I|
|Benzylpiperazine (BZP) (7493)||I|
|1-(alpha, alpha, alpha-trifluoro-m-tolyl) Piperazine (TFMPP) (7494)||I|
|Dextropropoxyphene, bulk (non-dosage forms) (9273)||II|
|Opium powdered (9639)||II|
The firm plans to repackage and offer as pure standards controlled substances in small quantities for drug testing and analysis.
Any manufacturer holding, or applying for, registration as a bulk manufacturer of these basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.
Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistance Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative, Office of Chief Counsel (CCD), and must be filed no later that November 26, 2003.
This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 Start Printed Page 61235(September 23, 1975), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.Start Signature
Dated: September 2, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-26962 Filed 10-24-03; 8:45 am]
BILLING CODE 4410-09-M